US FDA approves syringe version of Argenx's immune disorder drug
10/04/2025 22:51
April 10 (Reuters) - The U.S. Food and Drug Administration has approved a pre-filled syringe version of Netherlands-based Argenx SE's ARGX.BR blockbuster immune disorder drug, Vyvgart, giving patients the more convenient option of at-home self administration, the company said on Thursday. (Reporting by Kamal Choudhury and Mariam Sunny in Bengaluru; Editing by Tasim Zahid and Alan Barona) ((Kamal.Choudhury@thomsonreuters.com))